SINOMED(SH:688108)2024-04-23 11:48Financial Performance - The corrected total operating revenue for 2023 is CNY 343.26 million, representing a 77.99% increase compared to CNY 192.85 million in the same period last year[2]. - The corrected net profit attributable to the parent company is CNY -39.63 million, an increase of CNY 9.69 million or 19.64% from the previous forecast[5]. - The corrected net profit attributable to the parent company after deducting non-recurring gains and losses is CNY -49.71 million, an increase of CNY 8.33 million or 14.35% from the previous forecast[5]. - The basic earnings per share have been corrected to CNY -0.10, an increase of CNY 0.02 or 16.67% from the previous forecast[5]. - The weighted average return on net assets is corrected to -4.75%, an increase of 1.2 percentage points or 20.17% from the previous forecast[5]. Assets and Equity - The total assets at the end of the reporting period are CNY 1,185.82 million, an increase of 11.07% from CNY 1,067.61 million at the beginning of the period[4]. - The equity attributable to the parent company's owners is CNY 819.96 million, a decrease of 3.20% from CNY 847.08 million in the previous year[4]. Legal and Regulatory Matters - The company won a tax lawsuit with the French tax authorities, resulting in an increase of CNY 10.30 million in net profit attributable to the parent company[5]. - The company adjusted estimated expenses and share-based payment costs, leading to a decrease of CNY 0.62 million in net profit attributable to the parent company[6]. Investor Advisory - The company emphasizes the importance of reviewing the officially audited annual report for accurate financial data and warns investors of potential risks[7].